Breathe Well-Being Closed ₹50 Crores In Funding

We are thrilled to announce that Breathe Well-being, India’s leading digital, personalised, chronic disease management platform focused on Type 2 diabetes mitigation, has successfully raised ₹50 crores in funding. The round was led by Accel, 3one4 Capital, and General Catalyst.

This is a major milestone for the company and a testament to the progress they made in 2022.

- Breathe Well-being is the only digital health technology company in Asia with clinical evidence published in three prestigious journals - the American Diabetes Association, the European Society of Endocrinology, and the American Association of Clinical Endocrinology

- The app was downloaded by 2 million users globally!

- The company has received an overwhelmingly positive response from users, with 50,000 of them reporting success in mitigating diabetes, losing weight, lowering HbA1c levels, and preventing health complications.

- The program delivered impressive outcomes. >95% of participants on average reduced 1.5% of their HbA1c levels, >98% of participants discontinued medication and achieved an average weight loss of 5.5 kg.

‍

Breathe Well-being is poised to positively impact millions of  lives.

Founders Rohan Verma (Ex McKinsey & a certified CrossFit L2 trainer and mindfulness coach) and Aditya Kaicker (Ex Accenture & an ACE-certified behavioural health coach) built Breathe Well-being, a platform that offers a range of tools and resources to help users mitigate Type 2 diabetes. Their app provides personalised diabetes management plans, daily glucose tracking, adherence monitoring, and customised healthy food and exercise recommendations. It also offers access to a network of diabetes management specialists for users who need additional support.

“In our experience, game design and community-driven programs deliver far superior health outcomes. We are seeing the highest level of efficacy and the magic happens when there’s strict adherence to the protocols. We have seen more than 90% of participants were able to sustain their results beyond 24 months into the program. This is a big indicator of how engaging our entire plan is and people’s active willingness to get off the diabetes medication” said Aditya Kaicker, Co-founder and COO, Breathe Well-being.

‍

The future of chronic disease care!

Breathe Well-being aims to expand its digital therapeutic offerings to include other chronic conditions, such as hypertension, PCOS, gut disorders, and more, positioning itself as an emerging leader in the global health and wellness industry.

Its solution taps into a reawakened wellness economy, that has grown into a $4.5 trillion global business. It ​​is redefining how diabetes and other chronic diseases should be managed, delivering significantly better health outcomes and vital cost savings. The technology-driven, research-based, non-pharmaceutical approach is fundamentally augmenting the future of chronic-disease care.

We are excited to reinforce our support to the Breathe Well-being team as they positively impact lives and improve care delivery across India!

‍

DISCLAIMER

_{The views expressed herein are those of the author as of the publication date and are subject to change without notice. Neither the author nor any of the entities under the 3one4 Capital Group have any obligation to update the content. This publications are for informational and educational purposes only and should not be construed as providing any advisory service (including financial, regulatory, or legal). It does not constitute an offer to sell or a solicitation to buy any securities or related financial instruments in any jurisdiction. Readers should perform their own due diligence and consult with relevant advisors before taking any decisions. Any reliance on the information herein is at the reader's own risk, and 3one4 Capital Group assumes no liability for any such reliance.Certain information is based on third-party sources believed to be reliable, but neither the author nor 3one4 Capital Group guarantees its accuracy, recency or completeness. There has been no independent verification of such information or the assumptions on which such information is based, unless expressly mentioned otherwise. References to specific companies, securities, or investment strategies are not endorsements. Unauthorized reproduction, distribution, or use of this document, in whole or in part, is prohibited without prior written consent from the author and/or the 3one4 Capital Group.}